Patents by Inventor Peter Hagedorn

Peter Hagedorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tau antisense oligomers and uses thereof
    Patent number: 11077132
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: August 3, 2021
    Assignee: F. HOFFMANN-LA ROCHE AG
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
  • Oligonucleotides for modulating ATXN2 expression
    Patent number: 11066669
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: July 20, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Hagedorn, Heidi Rye Hudlebusch, Lykke Pedersen, Søren V. Rasmussen
  • CAMK2D antisense oligonucleotides and uses thereof
    Patent number: 11058767
    Abstract: The present disclosure relates to antisense oligonucleotides, which target CAMK2D mRNA in a cell, leading to reduced expression of CAMK2D protein. Reduction of CAMK2D protein expression is beneficial for the treatment of certain medical disorders, e.g., cardiovascular-related diseases or disorders.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: July 13, 2021
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Richard E. Olson, Brian R. Anderson, Peter Hagedorn, Marianne Lerbech Jensen, Ivar M. McDonald, Stephen E. Mercer
  • Antisense Oligonucleotides Targeting Alpha-Synuclein and Uses Thereof
    Publication number: 20210180065
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 17, 2021
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, JR., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. McDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20210123054
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: December 31, 2020
    Publication date: April 29, 2021
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Richard E. OLSON, Marianne L. JENSEN
  • OLIGONUCLEOTIDES FOR MODULATING ERC1 EXPRESSION
    Publication number: 20210095276
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of ERC1 in a target cell. The oligonucleotides hybridize to ERC1 pre-mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of disease associated with ERC1 overexpression, such as cancer or Dengue virus infection using the antisense oligonucleotide.
    Type: Application
    Filed: January 15, 2019
    Publication date: April 1, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Lykke PEDERSEN
  • OLIGONUCLEOTIDES FOR MODULATING PIAS4 EXPRESSION
    Publication number: 20210095274
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of PIAS4 in a target cell. The antisense oligonucleotides hybridize to PIAS4 pre-mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancers such as pancreatic cancer, breast cancer and liver fibrosis using the antisense oligonucleotide.
    Type: Application
    Filed: January 8, 2019
    Publication date: April 1, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Lykke PEDERSEN
  • OLIGONUCLEOTIDES FOR MODULATING GSK3B EXPRESSION
    Publication number: 20210095275
    Abstract: The present invention relates to antisense oligonucleotides that are capable of reducing expression of GSK3B in a target cell. The antisense oligonucleotides hybridize to GSK3B pre-mRNA. The present invention further relates to conjugates of the antisense oligonucleotide, pharmaceutical salts and pharmaceutical compositions and methods for treatment or alleviation of conditions such as cancer, inflammatory diseases, neurological diseases, neurological injury, neuronal degeneration, psychiatric diseases and Type 2 diabetes.
    Type: Application
    Filed: January 10, 2019
    Publication date: April 1, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Lykke PEDERSEN
  • OLIGONUCLEOTIDES FOR MODULATING TMEM106B EXPRESSION
    Publication number: 20210054383
    Abstract: The present invention relates to oligonucleotides that are complementary to and modulate the expression of TMEM106B. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurological disorders using the oligonucleotide.
    Type: Application
    Filed: August 6, 2020
    Publication date: February 25, 2021
    Inventors: Peter HAGEDORN, Marianne L. JENSEN, Lukasz KIELPINSKI, Amy EASTON, Benny CHIH
  • OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION
    Publication number: 20210024925
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Application
    Filed: April 3, 2020
    Publication date: January 28, 2021
    Inventors: Peter Hagedorn, Dennis Jul Hansen, Heidi Rye Hudlebusch, Lykke Pedersen, Søren Vestergaard Rasmussen, Mette Ladefoged
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20200399641
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: December 30, 2019
    Publication date: December 24, 2020
    Inventors: Roberto Iacone, Peter Hagedorn, Susanne Kammler, Soren Ottosen, Sindri Traustason, Heidi Hudlebusch, Lykke Pedersen
  • OLIGONUCLEOTIDES FOR MODULATING FNDC3B EXPRESSION
    Publication number: 20200385714
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of FNDC3B in a target cell. The oligonucleotides hybridize to FNDC3B pre-mRNA or mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of cancers, such as hepatocellular carcinoma or acute myeloid leukemia using the oligonucleotide.
    Type: Application
    Filed: December 10, 2018
    Publication date: December 10, 2020
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Peter HAGEDORN, Lykke PEDERSEN
  • ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20200362347
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 19, 2020
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, Jr., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. MCDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • ANTISENSE OLIGONUCLEOTIDES TARGETING ALPHA-SYNUCLEIN AND USES THEREOF
    Publication number: 20200354720
    Abstract: The present disclosure relates to antisense oligonucleotides, which target SNCA mRNA (e.g., at an intron exon junction) in a cell, leading to reduced expression of SNCA protein. Reduction of SNCA protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 12, 2020
    Applicants: Bristol-Myers Squibb Company, Roche Innovation Center Copenhagen A/S
    Inventors: Richard E. OLSON, Angela M. CACACE, Jere E. MEREDITH, Jr., Nino DEVIDZE, James K. LOY, Carl J. BALDICK, Annapurna PENDRI, Ivar M. McDONALD, Peter HAGEDORN, Marianne Lerbech JENSEN
  • Chiral library screen
    Patent number: 10815481
    Abstract: The invention relates to a method of identifying stereodefined phosphorothioate oligonucleotide variants with reduced toxicity by creating and screening libraries of stereodefined chiral phosphorothioate variants for compounds with reduced toxicity, either in vitro or in vivo.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 27, 2020
    Assignee: Roche Innovation Center Copenhagen A/S
    Inventors: Henrik Frydenlund Hansen, Troels Koch, Sabine Sewing, Nanna Albaek, Peter Hagedorn, Jacob Ravn, Christoph Rosenbohm, Annie Moisan, Marcel Gubler
  • Tau antisense oligomers and uses thereof
    Patent number: 10799523
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: October 13, 2020
    Assignee: F. HOFFMANN-LA ROCHE AG
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Dong Li, Jeffrey M. Brown, Marianne Lerbech Jensen, Niels Fisker Nielsen, Stephen E. Mercer
  • ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
    Publication number: 20200157546
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Application
    Filed: October 28, 2019
    Publication date: May 21, 2020
    Inventors: Rubén Alvarez Sánchez, Roberto Iacone, Peter Hagedorn, Susanne Kammler, Søren Ottosen, Sindri Traustason, Heidi Rye Hudlebusch, Lykke Pedersen, Marco Berrera, Andreas Dieckmann
  • OLIGONUCLEOTIDES FOR MODULATING ATXN2 EXPRESSION
    Publication number: 20200024600
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of ATXN2 in a target cell. The oligonucleotides hybridize to ATXN2 mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of neurodegenerative diseases such as spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), Alzheimer's frontotemporal dementia (FTD), parkinsonism and conditions with TDP-43 proteinopathies using the oligonucleotide.
    Type: Application
    Filed: June 3, 2019
    Publication date: January 23, 2020
    Inventors: Peter Hagedorn, Heidi Rye Hudlebusch, Lykke Pedersen, Søren V. Rasmussen
  • OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION
    Publication number: 20200010831
    Abstract: The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
    Type: Application
    Filed: July 3, 2019
    Publication date: January 9, 2020
    Applicant: Hoffmann-La Roche, Inc.
    Inventors: Peter HAGEDORN, Anja Mølhart HØG, Marianne L. JENSEN, Richard E. Olson
  • Antisense oligonucleotides for modulating HTRA1 expression
    Patent number: 10519450
    Abstract: The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: December 31, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Roberto Iacone, Peter Hagedorn, Susanne Kammler, Soren Ottosen, Sindri Traustason, Heidi Hudlebusch, Lykke Pedersen